Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC announces Amgen & AZ brodalumab phase III results


Monday, 12 May 2014 02:00am EDT 

AstraZeneca PLC:Phase III AMAGINE-1TM study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses.Brodalumab is only investigational treatment in development that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor.Primary endpoints were patients achieving at least 75 pct improvement from baseline in disease severity at week 12, as measured by Psoriasis Area Severity Index (PASI 75), and patients achieving clear or almost clear skin at week 12 according to the static Physician Global Assessment (sPGA 0 or 1).Results showed that 70.3 pct of patients in 210 mg group and 42.5 percent of patients in 140 mg group achieved PASI 90 responses compared to placebo. 

Company Quote

72.11
1.92 +2.74%
18 Dec 2014